Based on a study on “very rare cases of myocarditis”, the High Authority for health calls on Monday to favor the Pfizer vaccine, at the risk “five times lower”.
Posted
Update
Reading time : 1 min.
HAS plays the card of caution. The High Authority for Health recommended, Monday, November 8, to favor the use of the Pfizer-BioNTech vaccine for those under 30, because of higher cardiac risks with Moderna’s vaccine. THEThe risk of very rare cases of myocarditis “appears about five times less for Pfizer’s Comirnaty vaccine compared to Moderna’s Spikevax vaccine (100 µg) in 12-29 year olds”, justifies the authority, on the basis of a vast French study on the subject.
In its opinion, the HAS also gives the green light to the resumption of booster doses for over 30s with the Moderna vaccine. These injections had been suspended in mid-October, notably for lack of extension of indication at European level. Such approval has since been registered for the additional doses for adults. The effectiveness of this vaccine “looks slightly better” than that of Pfizer-BioNTech, underlines the HAS.
Moderna and Pfizer vaccines are “safe and effective” corn “Studies show a slight superiority of Spikevax in terms of efficacy and lower risks of myocarditis for Comirnaty, especially for people under 30 years old”, summarizes the HAS. At this stage, the booster dose injection campaign concerns people 65 years of age and over, as well as those with comorbidities that increase the risk of severe forms and death. The vaccines authorized in this context are those with messenger RNA.